Although comparative effectiveness research (CER) is still a relatively recent scientific discipline, its rapid expansion has helped thrust it into the spotlight. International Society For Pharmacoeconomics and Outcomes Research Chief Science Officer Dr. Richard Wilke says a core principle of CER […]
ICER Partners with VA Office for Drug Coverage, Price Negotiations
The Institute for Clinical and Economic Review (ICER) announced Tuesday it will work with the Department of Veterans Affairs (VA) Pharmacy Benefits Management Services (PBM) office in drug coverage and price negotiations with pharmaceutical companies. ICER, according to a press release, will […]
ICER Releases Update on PCKS9 Inhibitors
The Institute for Clinical and Economic Review (ICER) announced a "New Evidence Update" to its 2015 review of PCSK9 inhibitors for high cholesterol. In the updated information, ICER also delves into evidence pulled from the FOURIER evolocumab trial. According to a press release issued by ICER, […]
Transparency is the Key to Trust in RWE and CER
This article explores four key barriers to the credibility of RWE and CER, and provides recommendations on specific actions that those conducting such studies can take in order to increase transparency and build trust in their data. Find out more here. (Source: Richard White, future science group, […]
ICER Says Humira Needs 50-69% Discount
The Institute for Clinical and Economic Review recently evaluated rheumatoid arthritis drugs and awarded AbbVie's Humira a "C" rating in their comparative effectiveness analysis. According to the report, Humira would need a net price discount of 50% to 69% to be cost-effective. Find out more here. […]
ICER Releases Final Report on Rheumatoid Arthritis Treatments
The Institute for Clinical and Economic Review (ICER) recently released a final evidence report assessing treatments for rheumatoid arthritis (RA), finding inadequate evidence distinguishing benefits between newer agents. Prices were also found to be too high in relationship to the clinical value […]
Journal of Comparative Effectiveness Research – Jan 2017 Now Available!
The January 2017 issue of Journal of Comparative Effectiveness Research has been published! This issue reviews the past year's content and looks forward to the year ahead. Find out more here. (Source: Laura Dormer, Journal of Comparative Effectiveness Research) […]
What Will Improve Healthcare Decision-Making?
In a recent survey, stakeholders were asked their perspectives on the role that patient groups will play in the Comparative Effectiveness Research (CER) enterprise. Find out more about the results and recommendations for increasing CER's impact, here. (Source: Kimberly D Westrich, Journal of […]
Can Traditional CER Address Resource Allocation?
While the growth in U.S. healthcare costs is receiving substantial attention, many believe that instead of looking at general contributors, i.e. pharmaceutical pricing, we should look to resource allocation. Could Comparative Effectiveness Research (CER) methods help to answer this or is something […]
ICER Releases Draft Evidence Report on MS Treatments
The Institute for Clinical and Economic Review (ICER) recently released a draft evidence report on treatments for Multiple Sclerosis. The report is now open to public comment until December 21, 2016. Learn more about the contents of the report and how to comment here. (Source: ICER, 11/22/16) […]
From Concept to Policy – CER in the U.S.
From concept to policy: 10 years after the call for a US center for comparative effectiveness information. Dr Eugene Rich takes us through the American Recovery and Reinvestment Act of 2009, the Affordable Care Act and creation of PCORI in 2010, to the present. Read Dr Rich's article here. (Source: […]
ICER Releases Report on Plaque Psoriasis Treatments
The Institute for Clinical and Economic Review (ICER) recently released an Evidence Report assessing the value of eight targeted immunomodulatory drugs for the treatment of plaque psoriasis. Find out more here. (Source: ICER, 11/4/16) […]
ICER Opens Nominations for New Members of Voting Panels
The Institute for Clinical and Economic Review (ICER) is currently seeking nominations for new members to join its leading independent evidence review groups. Panel members include leading clinicians, patient and public representatives, methodologists in evidence-based medicine, and health […]
Panel Votes on ICER Values for NSCLC Drugs
The panel was formed with the intent of providing an independent review of three tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer (NSCLC). A final ICER report on the value and efficacy of these treatments for NSCLC based on this meeting is expected on or before […]
CER, HEOR, and Value-Based Frameworks in the US
This report addresses the following questions:- What impact have CER and HEOR had on drug reimbursement and uptake in the US so far? - Who are the key generators and users of CER and HEOR data? - How are new drug valuation frameworks such as ASCO, NCCN or ICER impacting drug reimbursement in the US? […]
Video: The Theory and Practice of CER
This HMRI Seminar series featured internationally recognized expert in comparative effectiveness research (CER), professor Francesco Chiappelli. Available to view here. (Source: YouTube, 10/11/16) […]
What Value is Big Data to CER?
There are several characteristics of EMR data that make it challenging to use for research, and our state of knowledge hasn't really changed much over the past 20 years when we used analysis of medical claims. What needs to happen to see the true value of big data in comparative-effectiveness […]
ICER Reviews Atopic Dermatitis Treatments
The Institute for Clinical and Economic Review (ICER) will be developing a report assessing the comparative clinical effectiveness and value of emerging therapies for the treatment of atopic dermatitis. Find out more here. (Source: ICER, 10/19/16) […]
GRACE Guidelines and High Quality CER
The Good Research for Comparative Effectiveness (GRACE) guidelines are one of the best practices for conducting comparative effectiveness research, however, most studies are not following these guidelines. A recent paper by Dreyer, Bryant and Velentgas (2016) took a look at 28 observational […]
4 Steps to Value-Based Drug Pricing Negotiation
The Center for American Progress recently outlined a framework to establish a negotiation process for Medicare and private health care payers and incorporates comparative effectiveness research (CER). Learn more here. (Source: Topher Spiro, Maura Calsyn, Thomas Huelskoetter, Center for American […]
ICER to Partner with University of Colorado Skaggs School of Pharmacy
The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and the Institute for Clinical and Economic Review (ICER) have formed a partnership to leverage CU Skaggs School of Pharmacy’s expertise in economic modeling of pharmaceutical interventions to support ICER’s growing […]
CER Fellows Named for 2016
Ten journalist have recently been selected for the second class of the AHCJ Fellowship on Comparative Effectiveness Research. Learn more about the planned trained topics of the fellowship class and about the 10 selected journalists here. (Source: Association of Health Care Journalists) […]
OPDIVO Highlights the Importance of Comparative Efficacy
OPDIVO, a Bristol-Myers Squibb's immunotherapy drug, recently failed to demonstrate a clinical improvement compared to chemotherapy in patients with newly-diagnosed lung cancer. This led to a dramatic drop in the company's stock and emphasized the growing importance of comparative efficacy research. […]
Check Out the New Journal of Comparative Effectiveness Research
The Journal of Comparative Effectiveness Research recently announced the publication of Volume 5, Issue 5 of JCER. This issue covers the usual wide range of subject areas, from medical apps, to value frameworks in cancer, diabetes and depression - and more! Available online, here. (Source: Future […]
JCER Sees Increase in Impact Factor
The Journal of Comparative Effectiveness Research has seen its impact factor increase over this past year. Their most recent publication, Volume 5, Issue 4 is now available online, here. (Source: Future Medicine, 2016) […]
HealthCore Awarded PCORI Funding
HealthCore, Inc recently announced a collaboration with PCORnet to build a sustainable patient-centered outcomes research network to conduct real-world comparative effectiveness research. Learn more about this collaboration and its funding here. (Source: Business Wire, 6/24/16) […]
ICER Releases Evidence Reports on Obeticholic Acid
The Institute for Clinical and Economic Review (ICER) recently released two Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid (OCA) (Ocaliva). Find out more here. (Source: ICER, 6/23/16) […]
ICER Releases Final Report on Multiple Myeloma Treatments
The Institute for Clinical and Economic Review (ICER) recently released Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-Based Price Benchmarks, a Final Evidence Report and Meeting Summary. Read more here. (Source: ICER, 6/9/16) […]
AMCP Outlines Changes to Format for Formulary Submissions
The Academy of Managed Care Pharmacy recently released its updated Format for Formulary Submission, Version 4.0. Read more here. (Source: NPC, 4/21/16) […]
NPC’s 2016 Annual CER Survey Results
NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the environment for health care decision-making found that stakeholders continue to have a high perception of the importance of CER, but believe that its full impact is still three to five years in the […]
